Connect Biopharma (CNTB) Set to Post Quarterly Earnings on Wednesday

Connect Biopharma (NASDAQ:CNTB) is expected to post its Q3 2026 resultson Wednesday, November 11th. Analysts expect Connect Biopharma to post earnings of ($0.27) per share and revenue of $0.12 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Connect Biopharma (NASDAQ:CNTB) last released its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.04. The firm had revenue of $2.75 million during the quarter, compared to the consensus estimate of $0.74 million. On average, analysts expect Connect Biopharma to post ($1.09) EPS for the current fiscal year and ($0.76) EPS for the next fiscal year.

Connect Biopharma Price Performance

Shares of CNTB opened at $0.77 on Wednesday. The company has a current ratio of 2.37, a quick ratio of 2.37 and a debt-to-equity ratio of 0.01. The company’s fifty day simple moving average is $1.30 and its 200 day simple moving average is $2.18. Connect Biopharma has a 1-year low of $0.73 and a 1-year high of $3.82. The company has a market cap of $48.75 million, a price-to-earnings ratio of -0.65 and a beta of 0.06.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CNTB shares. BTIG Research lowered their price objective on shares of Connect Biopharma to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, September 30th. Wall Street Zen downgraded shares of Connect Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday. Oppenheimer cut their target price on shares of Connect Biopharma to $5.00 and set an “outperform” rating for the company in a research note on Tuesday, September 22nd. Canaccord Genuity Group reduced their price target on Connect Biopharma from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, September 16th. Finally, HC Wainwright reiterated a “buy” rating on shares of Connect Biopharma in a research note on Wednesday, October 28th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Connect Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.88.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases driven by T-cell activity. The company’s research programs target conditions in immunology, including inflammatory bowel disease, atopic dermatitis and other immune-mediated disorders.

Its pipeline has included rademikibart, formerly known as CBP-201, an investigational monoclonal antibody designed to block the interleukin-4 receptor alpha pathway, and ropsacitinib, formerly known as CBP-307, an investigational oral TYK2 inhibitor.